Organisation paid for research Program year 2025 Source: CMS Open Payments

University of Florida

Neither a doctor nor a teaching hospital

Research payments

$65,727,829

9,719 payments

Through program year 2025, University of Florida is reported as receiving $65,727,829 in research payments, across 9,719 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$8,239,730	1,180
2024	Research	$10,701,720	1,441
2023	Research	$7,906,522	1,512
2022	Research	$7,787,173	1,168
2021	Research	$8,092,501	1,496
2020	Research	$9,153,500	1,372
2019	Research	$13,846,683	1,550

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $5,363,849 348 payments
Sarepta Therapeutics, Inc. $3,948,637 1,020 payments
AstraZeneca Pharmaceuticals LP $3,703,951 37 payments
Pfizer Inc. $3,245,974 221 payments
Novartis Pharmaceuticals Corporation $2,556,576 90 payments
CSL Behring $1,993,696 328 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $1,939,153 110 payments
Melinta Therapeutics, Inc. $1,934,670 8 payments
Gilead Sciences, Inc. $1,919,457 253 payments
E.R. Squibb & Sons, L.L.C. $1,627,186 28 payments

Studies the money was for Research payments · program years 2019–2025

CAPTIVA (Comparison of Anticoagulation vs anti-Platelet Therapies for Intracranial Vascular Atherostenosis) $2,921,589 2 payments
B16-439 $2,816,254 5 payments
Prospective Tick Bite Study Evaluating Exposure to Ticks By Measuring Antibody in Humans Targeting Tick Saliva in A Prospective Cohort $1,711,412 8 payments
P15-421 $1,067,750 3 payments
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $976,454 204 payments
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors $914,239 88 payments
Limit JIA Improving Outcomes in Limited JIA $724,905 2 payments
Eclipse $720,384 66 payments
Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies $716,062 86 payments
Srp-9001-301 $697,669 300 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $3,078,797 774 payments
Other $740,381 69 payments
Overhead $9,906 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.